Samsung Medical Center

Liminatus Pharma's IBA101, a second-generation CD47 inhibitor, demonstrated strong safety profile in primate studies with no observed anemia or thrombocytopenia at doses up to 100 mg/kg/week.

ImmuneOncia's next-generation CD47-targeting antibody IMC-002 demonstrated a 30% partial response rate when combined with lenvatinib in advanced hepatocellular carcinoma patients, significantly higher than the typical 10% seen with current second-line therapies.

GC Biopharma's Phase 3 clinical trial results for Hunterase (idursulfase beta) in Hunter Syndrome patients have been published in Genetics in Medicine, demonstrating significant improvements in functional mobility and metabolic markers.

Seer's new Proteograph ONE Assay and SP200 Automation Instrument can process over 1,000 samples per week, doubling throughput while reducing per-sample costs by approximately 60% compared to 2021.

• GC Cell has initiated first patient dosing in a Phase 1 clinical trial of GCC2005, a novel CD5 CAR-NK cell therapy targeting relapsed or refractory NK and T-cell malignancies, addressing a significant unmet need in aggressive lymphomas. • The innovative therapy utilizes allogeneic umbilical cord blood-derived NK cells engineered with a CD5-targeting chimeric antigen receptor and IL-15 co-expression to enhance persistence and anti-tumor efficacy. • The trial will enroll approximately 48 patients to evaluate safety, tolerability, maximum tolerated dose, and recommended Phase 2 dose, with promising preclinical data suggesting potential as a first-in-class treatment option.

A multi-center, double-blind, randomized trial is underway to compare ROTEM-guided tranexamic acid (TXA) administration with preemptive TXA in cardiovascular surgery patients.

ENCell's Phase 1 trial of EN001 mesenchymal stem cell therapy demonstrated safety with no dose-limiting toxicity or serious adverse events in nine CMT1A patients over 16 weeks.

Anbalcabtagene autoleucel (anbal-cel), a novel anti-CD19 CAR T-cell therapy, achieved an 84% objective response rate with 71% complete responses in patients with relapsed/refractory large B-cell lymphoma.

A recent study reveals that initial levels of TNF-α can predict the treatment response to Infliximab (IFX) in pediatric Crohn's Disease (CD).